2 Results Sort by:
Novel Vaccine Antigen Presentation Platforms
Application Combined antigen-adjuvant virus-like particle (VLP) vaccine platform for enhanced immune response. Key Benefits Chimeric VLPs (cVLPs) contain both antigen and adjuvant, thereby enhancing both cellular and humoral responses. cVLPs are safer than live replicating vectored vaccines because of their lack of infectivity. The cVLP manufacturing...
Published: 7/28/2023       Contributor(s): Baozhong Wang, Fu Shi Quan, Martin Moore, Richard Compans, Alan Aderem, Ioanna Skountzou, Jadranka Bozja
Repurposed Kinase Inhibitors as Vaccine Adjuvants
Application Repurposed, small molecule kinase inhibitors, such as epidermal growth factor receptor (EGFR) inhibitors, as topical vaccine adjuvants. Key Benefits Improves immune response and efficacy of vaccines and vaccine candidates. Employs compounds that are already approved for human use. Market Summary In order to create long lasting protection...
Published: 4/23/2024       Contributor(s): Brian Pollack, Richard Compans, Joanna Pulit-Penaloza, Ioanna Skountzou